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The retrospective analysis by Gutman and colleagues[1] provides a useful 
contribution to the knowledge of Atovaquone-proguanil (AP) use during 
pregnancy. 
The combination regimen has been licensed for nearly 20 years as a 
chemoprophylaxis agent.  The combination came  off patent in 2013 and is now  
widely available as a generic  drug.  To date, no  large prospective controlled 
safety studies in pregnant  women have been published.  It is unlikely  such 
studies  will become  available in the near future, in part because the  combination 
is not used in malaria endemic countries because of its high cost,  to provide  a 
more conclusive picture of AP ‘s safety during pregnancy; a situation  which the 
authors recognise.  To interpret pregnancy safety outcomes,  we have to  rely on 
less than ideal smaller  studies and pregnancy registry analysis. We also have 
some supportive safety insight from experience of the constituent drug’s use  in 
pregnant women prior to their combination.  
The authors compare  pregnancy outcomes of military women,  some using AP  




statistically significant increase in the risk of fetal loss and a composite adverse 
live birth outcome indicator.  The Hazard ratio for any AP  exposure is   1.5 with 
95% CI (0.90, 2.67)  and any live birth outcome OR of 1.55 95% CI (0.71, 3.71). 
The significance of these are both greater than 5%.  The authors  accurately 
describe the statistical reliability in their  discussion, as lacking in  power to 
detect associations between drug and adverse events, and that larger numbers of  
exposed pregnancies  are necessary  to understand AP exposure to pregnancy 
outcomes.  
It was therefore surprising to read their conclusion from the above findings that 
AP should not be used for prophylaxis, or treatment, in pregnant women and that 
it would be difficult to recommend a randomised controlled trial with AP,  based 
on these findings.  
The authors have previously  published  on AP outcomes  in pregnancy,  in which 
they have concluded that “rates of adverse events  after AP exposure during 
pregnancy are not higher than the expected rates in similar populations,”[2] and 
“no specific signal to suggest a teratogenic effect of AP, AP data during 
pregnancy”[3] and there is “limited evidence of the safety of AP in pregnancy” [4].  
Similar findings have been reported in  the largest analysis of AP in pregnancy  by 





We feel it is unreasonable to restrict an effective and tolerable drug from one of 
the most vulnerable groups of travellers. The authors make a recommendation  
based on low numbers and no statistical validity which is against the majority of 
published evidence.  The decision  to prescribe  should be left to the individual 
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